Gilles Salles, MD, PhD

Nowakowski GS et al. ROBUST: A phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma. J Clin Oncol 2021;39(12):1317-28. Abstract

Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med 2021;384(9):842–58. Abstract

Tilly H et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 2022;386(4):351-63. Abstract

Grzegorz S Nowakowski, MD

Neelapu SS et al. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: The phase 2 ZUMA-12 trial. Nat Med 2022;28(4):735-42. Abstract

Nowakowski GR et al. First-Mind: Final analysis from a phase Ib, open-label, randomized study to assess safety of tafasitamab or tafasitamab + lenalidomide in addition to R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma. ASH 2022;Abstract 1619.

Palmer AC et al. Cell-of-origin subtypes and therapeutic benefit from polatuzumab vedotin. N Engl J Med 2023;389(8):764-6. Abstract

Laurie H Sehn, MD, MPH

Ayers E et al. Loncastuximab in high-risk and heavily-pretreated relapsed/refractory diffuse large B-cell lymphoma: A real world analysis from 21 US centers. ASH 2023;Abstract 312.

Caimi PF et al. Long‐term responses with loncastuximab tesirine: Updated results from LOTIS‐2, the pivotal phase 2 study in patients with relapsed/refractory diffuse large B‐cell lymphoma. ICML 2023.

Duell J et al. Five‐year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: Final results from the phase II L‐MIND study. ICML 2023.

Duell J et al. Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: Final 5-year efficacy and safety in the phase II L-MIND study. Haematologica 2023;[Online ahead of print. Abstract

Furqan F, Hamadani M. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: A review of clinical data. Ther Adv Hematol 2022;13:20406207221087511. Abstract

Iacoboni G et al. Impact of prior bendamustine exposure on bispecific antibody treatment outcomes for patients with B-cell lymphoma. ASH 2023;Abstract 310.

Northend M et al. Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL. Blood Adv 2022;6(9):2920-6. Abstract

Palmer AC et al. Cell-of-origin subtypes and therapeutic benefit from polatuzumab vedotin. N Engl J Med 2023;389(8):764-6. Abstract

Qualls DA et al. Responses and outcomes after second-line therapy in transplant-eligible patients with DLBCL relapse over 1 year after first-line therapy. ASH 2022;Abstract 4970.

Sehn LH et al. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: Survival update and new extension cohort data. Blood Adv 2022;6(2):533-43. Abstract

Westin J, Sehn LH. CAR T cells as a second-line therapy for large B-cell lymphoma: A paradigm shift? Blood 2022;139(18):2737-46. Abstract

Jason Westin, MD, MS

Abramson JS et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: Primary analysis of the phase 3 TRANSFORM study. Blood 2023;141(14):1675-84. Abstract

Dickinson MJ et al. A novel autologous CAR-T therapy, YTB323, with preserved T-cell stemness shows enhanced CAR T-cell efficacy in preclinical and early clinical development. Cancer Discov 2023;13(9):1982-97. Abstract

Elsawy M et al. Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma. Blood 2022;140(21):2248-60. Abstract

Houot R et al. Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: A phase 2 trial. Nat Med 2023;29(10):2593-601. Abstract

Locke F et al. Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501/501A in relapsed/refractory large B-cell lymphoma (r/r LBCL). ASCO 2023;Abstract 2517.

Neelapu SS et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood 2023;141(19):2307-15. Abstract

Seghal A et al. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): An open-label, phase 2 study. Lancet Oncol 2023;23(8):1066-77. Abstract

Svoboda J et al. Combination of everolimus and itacitinib in patients with Hodgkin lymphoma relapsed/refractory to brentuximab vedotin (BV) and checkpoint inhibitors (CPI). ICML 2023;Abstract 445.

Westin J et al. Primary overall survival analysis of the phase 3 randomized ZUMA-7 study of axicabtagene ciloleucel versus standard-of-care therapy in relapsed/refractory large B-cell lymphoma. ASCO 2023;Abstract LBA107.

Westin J et al. Survival with axicabtagene ciloleucel in large B-cell lymphoma. N Engl J Med 2023;389(2):148-57. Abstract

Michael Dickinson, MD

Dickinson MJ et al. Combining CD19‐4‐1BBL (RO7227166) with glofitamab is safe and shows early efficacy in patients suffering from relapsed or refractory B-cell non‐Hodgkin lymphoma. ICML 2023;Abstract 091.

Dickinson MJ et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 2022;387:2220-31. Abstract

Frampton JE. Epcoritamab: First approval. Drugs 2023;83(14):1331-40. Abstract

Shirley M. Glofitamab: First approval. Drugs 2023;83(10):935-41. Abstract

Thieblemont C et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: Dose expansion in a phase I/II trial. J Clin Oncol 2023;41(12):2238-47. Abstract